Revolutionizing Drug Discovery with Bioprinted Organ Models

In the heart of Houston, Texas, a transformative venture is unfolding in the realm of drug discovery and development. I had the privilege of witnessing this firsthand at the Texas Life Science Forum, where Systemic Bio, a subsidiary of 3D Systems, showcased their groundbreaking work. Their mission? To revolutionize the way we test drugs using bioprinted organ models.

The challenge in drug development has always been the accuracy and reliability of preclinical testing. Traditional methods often rely on animal models or simplified cell cultures, which, while useful, don’t fully replicate human organ complexity. This gap can lead to inefficiencies and inaccuracies in drug testing, potentially delaying life-saving treatments.

Enter Systemic Bio. Founded in 2022, this innovative company is addressing these challenges head-on. With a $15 million seed investment from 3D Systems, they have established a state-of-the-art laboratory dedicated to manufacturing hydrogel scaffolds and conducting organ-on-a-chip research and development. This isn’t just another lab; it’s a hub of innovation, equipped with the latest in bioprinting technology.

So, how does Systemic Bio’s approach differ? It lies in their use of hydrogels and human cells to create vascularized organ models. These aren’t just simple representations; they are meticulously crafted to mimic the intricate structures and functions of human organs. This precision is achieved through advanced bioprinting technology, enabling the creation of models known as h-VIOS™. These can be produced reproducibly in large quantities, offering a more consistent and accurate platform for drug testing.

The implications of this technology are profound. By providing more accurate models of human organs, Systemic Bio is paving the way for more effective and safer drugs. This is not just about improving the efficiency of drug discovery; it’s about revolutionizing the process, making it more reliable and ultimately, more successful in finding treatments that work for people.

As I listened to their presentation, I couldn’t help but be struck by the potential impact of Systemic Bio’s work. In the quest for better healthcare solutions, their contribution stands out as a beacon of innovation and hope. As they continue to push the boundaries of what’s possible in drug testing, we can all look forward to a future where treatments are developed faster, safer, and more effectively, thanks to the pioneering efforts of companies like Systemic Bio.